clinical trial · NCT07428499
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
ADARx Pharmaceuticals, Inc.·phase3·not yet recruiting·n = 90
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2HAEADX-324 Dose Level 1ADX-324 Dose Level 2
brief summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
started
Apr 1, 2026
primary completion
Jun 30, 2030
completion
Jun 30, 2030
last updated
Mar 2, 2026
official title
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol